ArticleCancer medicine2025
An Integrated Clinical-Radiomics-Deep Learning Model Based on
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAn integrated model combining clinical variables, radiomic features, and deep learning was developed to predict EGFR mutation status in patients with lung adenocarcinoma based on pretreatment
methodsIn this retrospective study, data from 218 patients-including PET/CT images, EGFR mutation status, and clinical characteristics-were analyzed. Three predictive models were constructed: a clinical model (C), a clinical-radiomics model (CR), and a clinical-radiomics-deep learning model (CRD).
resultsThe CRD model integrated screened clinical features, as well as ConvNext-based deep learning scores and radiomic scores selected via LASSO regression. It exhibited significantly superior predictive performance to the C model (AUC = 0.599; DeLong test: Z = -3.522, p < 0.001, corrected p = 0.001) and the CR model (AUC = 0.739; DeLong test: Z = -2.197, p = 0.028, corrected p = 0.028), with an AUC of 0.821 for the CRD model. Calibration curves and decision curve analysis confirmed its robustness and potential clinical benefit. A nomogram based on the CRD model was established, enabling individualized risk prediction of EGFR mutation.
conclusionsThis study highlights the potential of integrating clinical, radiomic, and deep learning features as a noninvasive approach for accurately predicting EGFR mutation status in lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.